Management of Acute Coronary Syndromes
Series: Contemporary Cardiology;
- Publisher's listprice EUR 160.49
-
66 563 Ft (63 393 Ft + 5% VAT)
The price is estimated because at the time of ordering we do not know what conversion rates will apply to HUF / product currency when the book arrives. In case HUF is weaker, the price increases slightly, in case HUF is stronger, the price goes lower slightly.
- Discount 20% (cc. 13 313 Ft off)
- Discounted price 53 250 Ft (50 714 Ft + 5% VAT)
Subcribe now and take benefit of a favourable price.
Subscribe
66 563 Ft
Availability
Estimated delivery time: In stock at the publisher, but not at Prospero's office. Delivery time approx. 3-5 weeks.
Not in stock at Prospero.
Why don't you give exact delivery time?
Delivery time is estimated on our previous experiences. We give estimations only, because we order from outside Hungary, and the delivery time mainly depends on how quickly the publisher supplies the book. Faster or slower deliveries both happen, but we do our best to supply as quickly as possible.
Product details:
- Edition number Softcover reprint of the original 1st ed. 2003
- Publisher Humana Press
- Date of Publication 4 November 2002
- Number of Volumes 1 pieces, Book
- ISBN 9781588293091
- Binding Paperback
- See also 9781588291301
- No. of pages783 pages
- Size 254x178 mm
- Weight 1495 g
- Language English
- Illustrations XV, 783 p. Illustrations, black & white 0
Categories
Long description:
In this second edition of his highly acclaimed book, Christopher P. Cannon, MD, and a team of preeminent clinical investigators have thoroughly revised and expanded every chapter to reflect the recent explosion of clinical trials on the management of acute coronary syndromes (ACS). This includes: the newer tests, such as C reactive protein; a multimarker approach to diagnosis and risk stratification; new antiplatelet agents; and combinations of thrombolytic-antithrombotic regimens. Also discussed are the latest developments in interventional cardiology, the use of cost-effectiveness in clinical trials to choose appropriate therapies, and the employment of critical pathways analysis to improve compliance with evidence-based medicine and guideline recommendations.
MoreTable of Contents:
I Pathophysiology.- 1 The Spectrum of Myocardial Ischemia: The Paradigm of Acute Coronary Syndromes.- 2 Linking Biochemistry, Vascular Biology, and Clinical Events in Acute Coronary Syndromes.- 3 Triggers of Acute Coronary Syndromes.- 4 Insights into the Pathophysiology of Acute Ischemia Syndromes Using the TIMI Flow Grade, TIMI Frame Count, and TIMI Myocardial Perfusion Grade.- II Diagnosis.- 5 Emergency Department Presentations of Acute Cardiac Ischemia.- 6 Early Identification and Treatment of Patients with Acute Coronary Syndromes.- 7 Serum Markers for Diagnosis and Risk Stratification in Acute Coronary Syndromes.- 8 Technologies to Diagnose Acute Ischemia.- III ST-Segment Elevation Myocardial Infarction.- 9 Thrombolytic Therapy.- 10 Primary Angioplasty.- 11 Expanding the Access to Percutaneous Coronary Intervention for Patients Admitted to Community Hospitals.- 12 Antiplatelet and Anticoagulant Therapy.- 13 ?-Adrenergic Blockers, Calcium Channel Blockers, and Nitrates.- 14 Angiotensin Converting Enzyme Inhibitors After and During Acute Coronary Syndromes, and, in Particular, Myocardial Infarction.- 15 Risk Stratification: Exercise Testing, Imaging, and Cardiac Catheterization.- IV Non-ST-Segment Elevation Myocardial Infarction.- 16 Anticoagulant Therapies.- 17 Antiplatelet Therapy.- 18 Thrombolytics and Invasive vs Conservative Strategies in Unstable Angina.- 19 Current Device Strategies in the Management of Acute Coronary Syndromes.- V Special Aspects of Acute Coronary Syndromes.- 20 Women and Acute Coronary Syndromes.- 21 The Modern Strategy for Cardiogenic Shock.- 22 Myocardial Infarction in the Younger Patient.- 23 Cholesterol Lowering.- 24 “Secondary Prevention” of Myocardial Infarction.- 25 Cost and Cost-Effectiveness in Acute Coronary Syndromes.- 26Smoking Cessation.- 27 Critical Pathways for Acute Coronary Syndromes.
More
Untersuchungen zu biotinylierten Photocrosslinkern und Petrobactin-Derivaten
10 364 HUF
9 846 HUF
